Results of a phase III trial indicate that both the immediate and extended release formulations of febuxostat reduce serum uric acid levels in patients with gout, including those with impaired renal function.
Results of a post-hoc analysis suggest that high early disease activity is associated with poor response to methotrexate and the occurrence of radiographic progression among patients with rheumatoid arthritis.
Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213502
Study results indicate that patients with severe juvenile idiopathic arthritis who start biologic DMARDs within 2 years of symptom onset have better long-term outcomes than those who begin treatment later.
The proportion of patients initiating osteoporosis medication following hip fracture has declined in recent years, despite treatment reducing subsequent fracture risk, analysis of a US medical claims database suggests.